LAKE FOREST, Calif., July 29 /PRNewswire-FirstCall/ -- In response to an article in this morning’s New York Post, Apria Healthcare Group Inc. issued the following statement:
As a matter of policy Apria does not comment on rumors and speculation concerning possible transactions involving the Company. However, in light of speculative trading in Apria stock following publication of a New York Post story, Apria is making an exception to its policy on this occasion.
Apria does receive inquiries from time to time concerning the possible acquisition of the Company, and in the exercise of their fiduciary duty Apria’s board of directors considers, from time to time, whether the best interests of stockholders would be served by pursuing such a transaction. At this time, there is no transaction pending and Apria is not engaged in any effort looking to, or negotiations with any party concerning, a sale of the Company.
Apria provides home respiratory therapy, home infusion therapy and home medical equipment through approximately 455 branches serving patients in 50 states. With nearly $1.4 billion in annual revenues, it is the nation’s leading homecare company.
This release may contain statements regarding anticipated future developments that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Results may differ materially as a result of the risk factors included in the Company’s filings with the Securities and Exchange Commission and other factors over which the Company has no control.
For Further Information, Contact: Lawrence M. Higby Chief Executive Officer 949.639.4960 Amin I. Khalifa Chief Financial Officer 949.639.4990
Apria Healthcare Group Inc.
CONTACT: Lawrence M. Higby, Chief Executive Officer, +1-949-639-4960, orAmin I. Khalifa, Chief Financial Officer, +1-949-639-4990, both of ApriaHealthcare Group Inc.
